



Ethical issues in medical cannabis use

Iftach Sagy^{a,b,d,*}, Tal Peleg-Sagy^{c,d}, Leonid Barski^{a,d}, Lior Zeller^{a,d}, Alan Jotkowitz^{a,d}

^a Division of Internal Medicine, Soroka University Medical Center, Beer-Sheva, Israel

^b Clinical Research Center, Soroka University Medical Center, Beer-Sheva, Israel

^c Beer-Sheva Mental Health Center, Israel

^d Ben Gurion University of the Negev, Beer-Sheva, Israel



ARTICLE INFO

Keywords:

Medical cannabis

Ethical considerations

ABSTRACT

The increasing use of medical cannabis (MC) in the past decade raises several ethical considerations for the clinician. Regulatory issues stem from a gap between MC registration and certification in each country. Professional issues derive from the lack of sufficient knowledge of MC characteristics and the intersection between the physician, the patient and commercial interests. Finally, there are medical and psychological implications which are related to the use of MC regimens. We will discuss these issues in the light of the current era, in which policy has rapidly shifted toward legalization of cannabis, which influences the decisions of both clinicians and patients.

1. Introduction

Chronic pain conditions affect an increasing portion of the population worldwide [1,2]. Due to a lack of efficacy and frequent adverse effects of the standard therapies, the use of medical cannabis (MC) has emerged in the past decade in a bottom-up fashion. According to a 2005 survey, half of American adults have suffered from pain in the previous couple of weeks, 20% have rated their pain as “severe” and 6% (12 millions) have treated their pain with cannabis [3]. Similar rate of MC use was also reported in a Canadian survey [4].

There are many other disorders where great potential for the relief of symptoms by the use of cannabis exist but powerful clinical trial data is missing. In the past, large clinical trials which can be very expensive and time consuming have been organized and supported by pharmaceutical companies which have exclusive patent rights to the product. In contradistinction, medical cannabis is not under any patent protection and there is less incentive for pharmaceutical companies to perform the much needed clinical trials. This puts the individual physician in an ethical quandary as for many conditions the relevant clinical data is missing and in many cases the physicians is legally required to use the more expensive and perhaps less efficacious medication. In order to overcome this problem large clinical trials on a variety of medical conditions are necessary not only to look for efficaciousness but also potential side effects and long term outcomes. The growing reluctance among many physicians to prescribe opioids for non-oncological pain disorders also highlights the importance of obtaining the necessary clinical trial data. However, the frequent use of MC also raises ethical

issues for consideration by the medical professionals.

In this review we will discuss these issues in the light of the increasing medical use of MC. First, we will discuss regulatory considerations of MC use. Second, we will turn to professional perspectives. Third, we will consider the medical and psychological considerations of MC use.

2. Regulatory and ethical considerations

The synthetic oral tetrahydrocannabinol (THC) named “Marinol”, has been approved by the Food and Drug Administration (FDA) in 1985 [5]. In the past decade, the oromucosal spray named Sativex which contains THC and cannabidiol in a nearly 1:1 ratio, has been approved for use in the United Kingdom, Canada and several other countries [6]. As opposed to the two approved cannabis agents mentioned above, most popular MC are dried cannabis plant derivatives, consist with THC and CBD in variable levels. Different strains of MC may influence differently due to their THC and CBD content and ratio of these two ingredients [7].

There is insufficient high quality data regarding the efficacy, dose-dependent curve, drugs interactions, expected adverse effects and safety of the commercial available MC products. For instance, smoked MC, a frequent method to utilize CM, has a very low bio-availability and was linked to a wide range of respiratory adverse effects, e.g. cough, phlegm and bronchitis [8]. The poor RCT's data also impairs the ability to define clear clinical indications to use MC. Consequently, physicians can prescribe MC for any indication they choose (e.g. vague indication

* Corresponding author at: Clinical Research Center, Rager Av. 151, Beer-Sheva 84101, Israel.
E-mail address: iftachsa@clalit.org.il (I. Sagy).

as “chronic pain”) rather than clear evidence based conditions [9]. Due to these gaps there is a long way to go until more MC regimens will receive FDA approval. Since there is a lack of data especially from RCT's regarding the efficacy and safety of each regimen according to its THC:CBD ratio, these gaps may impair the decisions made by physicians regarding tailoring the optimal therapy for each patient.

A different regulatory issue stems from the US federal governmental laws. Marijuana is defined as illegal drug by the U.S FDA. It is classified as Schedule I under the Controlled Substances Act, meaning that “it has no currently accepted medical use and a high potential for abuse” [10]. Due to its status, physicians cannot prescribe MC and rather can only give certification to its use.

3. Professional perspectives

The use of MC poses several ethical considerations to the physicians in their practice. As mentioned above, physicians are expected to prescribe unstandardized agents with no FDA approval, but with potentially unexpected effect and adverse reactions. Physicians are also required to discuss with their patients' potential risks and benefits before prescribing any treatment or medication. Since MC dosing and potency is not regulated, there is an unavoidable knowledge gap. Not surprisingly, most of the family physicians in Colorado (a state with high rate of marijuana use) stress that marijuana's health risks outweigh their benefits, and nearly all agreed that routine utilization of MC needs further education [11]. There is also a lack of data on the long term effects of cannabis use [12] which impacts on physician and patient decision making. Moreover, the relationship of some psychiatric conditions with cannabis utilization remained unclear, as previous studies reported an increased risk for developing depression among chronic cannabis users [13].

In several countries MC certification is given only to specific physicians or nurses, who are authorized by the local health ministries [14]. This situation may turn into a reality, where certain caregivers will be involved mostly in the distribution of MC certifications rather than providing routine health care.

The most popular administering method of MC is by smoking [15] and this topic has several important ethical implications. Besides the effect of smoked MC on the respiratory tracts of the users, it may also be associated with second hand smoke effects on the environment. For instance, second hand cannabis smoke was reported to produce detectable levels of THC in blood and urine, and minor impairment on psychomotor abilities and working memory [16]. Second hand cannabis exposure was also found to be associated with lower cognitive functioning among exposed children [17] and increase emergency visits among children exposed to second hand cannabis smoke after legalization [18]. These findings imply that smoked MC contradicts the harm principle, in which an individual is free to abuse illicit agent unless it does not harm others. On the other hand, smoked MC is administered easily, with a shorter half-life but higher bio-availability compared to oral MC regimens [7]. This issue emphasizes the principle of respect of autonomy, since some would prefer to use smoked or vaporized MC, which will be most suitable for their needs. These two contradicting ethical considerations need to be balanced, and should be kept in mind during routine patient-physician interaction on this topic.

An additional concern relates to the intersection of medicine and commercial interests. Since there is no clear guidelines of when to prescribe MC, the vague indications and relatively high availability of MC may lead to over-use, misuse and eventually to illegal trading with third party similar to the broad use of opioids [19,20]. These undesirable trends may be pushed by commercial interests, which might jeopardize both clinicians' integrity and patients' well-being. For instance, commercialization of cannabis in the U.S has been associated with lower risk perception of cannabis, and was associated inversely with increase use of cannabis among youth [21,22]. Forty percent of adolescents reported obtaining marijuana from someone with a MC license

[23]. Consequently, this finding implies that patients with approved MC material may pass or trade the drug with a third un-authorized party. MC exposure was found to be related to cannabis availability of any type and increased frequency of use, especially among the vulnerable group of adolescents. In this case, there is an actual concern that MC dispensaries may be the stalking horse for increased commercial distribution of cannabis to the entire public, rather than to the those who have relevant health concerns. On the other hand, when dealing with those who do receive medical certification to use MC, no insurance companies provide coverage to MC, which further exacerbates the burden on patients.

4. Medical and psychological implications

The use of MC has several risks due to short-term and long-term utilization [24]. Almost 10% of those who use cannabis will become addicted to it [25]. In addition, the development of cannabis withdrawal syndrome makes more difficult the cessation of cannabis use [26]. Apparently, adolescents are the most vulnerable group, as they show 2–4 folds likely to develop cannabis dependence compared with adults [27]. Moreover, chronic cannabis utilization was found to deteriorate the brain functioning connectivity especially among young adults [28]. This explains why frequent use of cannabis during adolescence period was associated with declines in IQ measurements [29]. Furthermore, several epidemiological studies have reported the role of cannabis utilization as a gateway drug to the consumption of other substances later in life, due to reduced dopamine activity in the brain's reward region [30,31]. The use of MC or legal recreational cannabis can also be seen in the context of self-medication hypothesis of addictive disorders, where patients utilize drugs to relieve painful (physical or emotional) states. These states are important psychological predictors for utilization and in developing dependency on addictive drugs instead of treating with the initial trigger that have created these conditions [32]. Chronic and even short term use of cannabis were also linked to depression, anxiety, acute psychosis disorders and schizophrenia (the latter was reported among users with preexisting genetic vulnerability) [33,34]. There is evidence that even relatively short term exposure to cannabis is associated with poor educational performances and increased risk to dropping out of school [35].

These short and long term consequences of MC use can put the physician who prescribed them in a constant conflict. Although every drug has adverse reactions, as stressed above, quality RCT's on MC regimens and more specifically on substances with alternating THC:CBD ratio are scarce. Consequently, when discussing with patients the expected effect and adverse effect of each regimen there is a substantial information gap that impair receiving proper informed consent from patients prior to any initiation of MC therapy.

5. Conclusion

The increasing use of MC in the past decade consists of regulatory, professional and medical ethical considerations. Although most of these concerns are common to any medical regimen with potential risk, some are unique to MC utilization. Physicians who certify their patients to use MC, encounter several conflicting ethical issues as discussed above. The use of MC is associated with lack of sufficient knowledge regarding the exact content and purity of MC derivatives, expected dose response relationship, adverse events and interaction with other drugs. These gaps impair the patients ability to reach a fully informed decision since many issues of MC pharmacokinetics and pharmacodynamics are still unclear. The lack of sufficient knowledge may lead to undesirable harm to the patients, which contradict the physician's principle of non-maleficence. On the other hand, since many patients prefer administering MC via smoking methods, their right to autonomy (choosing the best route of administering for them) interfere with the no harm principle, which stems from the right to self-abuse substances. The involvement of

commercial cannabis dispensaries can expose patients to outside influences, thereby impairing their autonomy to make decision unrelated to other influences. The use of legalized substances such as alcohol, tobacco and soon cannabis, accounts for a greater burden than other illegal drugs, due to their widespread use rather than their actual harms [36]. It is important to bear in mind that while the policy is rapidly shifting toward legalization of cannabis and expanding the use of MC, there are still numerous ethical considerations that need to be resolved along the way.

Conflict of interest statement

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

References

- [1] Elliott AM, Smith BH, Penny KI, Smith WC, Chambers WA. The epidemiology of chronic pain in the community. *Lancet* 1999;354(9186):1248–52.
- [2] Torrance N, Smith BH, Bennett MI, Lee AJ. The epidemiology of chronic pain of predominantly neuropathic origin. Results from a general population survey. *J Pain* 2006;7(4):281–9.
- [3] ABC News, USA Today, Stanford Medical Center Poll. Broad experience with pain sparks search for relief [online] Available at <http://abcnews.go.com/images/Politics/979a1TheFightAgainstPain.pdf>; 2005.
- [4] Osborne AC, Smart RG, Adlaf EM. Self-reported medical use of marijuana: a survey of the general population. *CMAJ* 2000 Jun 13;162(12):1685–6.
- [5] Marinol (Dronabinol) Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/018651s0211bl.pdf; Sep 2004.
- [6] Perez J, Ribera MV. Managing neuropathic pain with Sativex®: a review of its pros and cons. *Expert Opin Pharmacother* 2008;9(7):1189–95.
- [7] Ashton CH. Pharmacology and effects of cannabis: a brief review. *Br J Psychiatry* 2001 Feb;178:101–6.
- [8] Russo EB. 11 the solution to the medicinal cannabis problem. *Ethical issues chron. pain manage.* 165. 2006.
- [9] The Official Website of the Executive Office of Health and Human Services. Guidance for physicians on the medical use of marijuana Available at <http://www.mass.gov/eohhs/gov/departments/dph/programs/hcq/medical-marijuana/info-for-physicians.html>; June 2015.
- [10] U.S Department of Justice. Title 21 United States code (USC) controlled substances act Available at <https://www.deadiversion.usdoj.gov/21cfr/21usc/812.htm>; July 2017.
- [11] Kondrad E, Reid A. Colorado family physicians' attitudes toward medical marijuana. *J Am Board Fam Med* 2013 Jan-Feb;26(1):52–60.
- [12] Calabria B, Degenhardt L, Hall W, Lynskey M. Does cannabis use increase the risk of death? Systematic review of epidemiological evidence on adverse effects of cannabis use. *Drug Alcohol Rev* 2010;29(3):318–30.
- [13] Lev-Ran S, Roerecke M, Le Foll B, George T, McKenzie K, Rehm J. The association between cannabis use and depression: a systematic review and meta-analysis of longitudinal studies. *Psychol Med* 2014;44(4):797–810.
- [14] Sally Bean JDM. Medical cannabis: identifying ethical and policy implications for healthcare organizations in Canada. *J Pain Manag* 2016;9(4):473.
- [15] Leung L. Cannabis and its derivatives: review of medical use. *J Am Board Fam Med* 2011 Jul-Aug;24(4):452–62.
- [16] Herrmann ES, Cone EJ, Mitchell JM, Bigelow GE, LoDico C, Flegel R, et al. Non-smoker exposure to secondhand cannabis smoke II: effect of room ventilation on the physiological, subjective, and behavioral/cognitive effects. *Drug Alcohol Depend* 2015;151:194–202.
- [17] Fried PA, Watkinson B. 36-and 48-month neurobehavioral follow-up of children prenatally exposed to marijuana, cigarettes, and alcohol. *J Dev Behav Pediatr* 1990;11(2):49–58.
- [18] Wang GS, Roosevelt G, Heard K. Pediatric marijuana exposures in a medical marijuana state. *JAMA Pediatr* 2013;167(7):630–3.
- [19] Rosenblatt RA, Catlin M. Opioids for chronic pain: first do no harm. *Ann Fam Med* 2012 Jul-Aug;10(4):300–1.
- [20] Sullivan MD, Edlund MJ, Fan M, DeVries A, Braden JB, Martin BC. Risks for possible and probable opioid misuse among recipients of chronic opioid therapy in commercial and medicaid insurance plans: the TROUP study. *Pain* 2010;150(2):332–9.
- [21] Johnston LD, O'Malley PM, Bachman JG, Schulenberg JE. Monitoring the future national results on adolescent drug use: overview of key findings. *Institute for Social Research*; 2011. p. 2012.
- [22] Schuermeyer J, Salomonsen-Sautel S, Price RK, Balan S, Thurstone C, Min S, et al. Temporal trends in marijuana attitudes, availability and use in Colorado compared to non-medical marijuana states: 2003–11. *Drug Alcohol Depend* 2014;140:145–55.
- [23] Thurstone C, Lieberman SA, Schmiege SJ. Medical marijuana diversion and associated problems in adolescent substance treatment. *Drug Alcohol Depend* 2011;118(2):489–92.
- [24] Volkow ND, Baler RD, Compton WM, Weiss SR. Adverse health effects of marijuana use. *N Engl J Med* 2014;370(23):2219–27.
- [25] Hall W, Degenhardt L. Adverse health effects of non-medical cannabis use. *Lancet* 2009;374(9698):1383–91.
- [26] Gorelick DA, Levin KH, Copersino ML, Heishman SJ, Liu F, Boggs DL, et al. Diagnostic criteria for cannabis withdrawal syndrome. *Drug Alcohol Depend* 2012;123(1):141–7.
- [27] Chen C, Storr CL, Anthony JC. Early-onset drug use and risk for drug dependence problems. *Addict Behav* 2009;34(3):319–22.
- [28] Zalesky A, Solowij N, Yücel M, Lubman DI, Takagi M, Harding IH, et al. Effect of long-term cannabis use on axonal fibre connectivity. *Brain* 2012;135(7):2245–55.
- [29] Meier MH, Caspi A, Ambler A, Harrington H, Houts R, Keefe RS, et al. Persistent cannabis users show neuropsychological decline from childhood to midlife. *Proc Natl Acad Sci U S A* 2012 Oct 2;109(40):E2657–64.
- [30] DiNieri JA, Wang X, Szutorisz H, Spano SM, Kaur J, Casaccia P, et al. Maternal cannabis use alters ventral striatal dopamine D2 gene regulation in the offspring. *Biol Psychiatry* 2011;70(8):763–9.
- [31] Agrawal A, Neale MC, Prescott CA, Kendler KS. A twin study of early cannabis use and subsequent use and abuse/dependence of other illicit drugs. *Psychol Med* 2004;34(7):1227–37.
- [32] Khantzian EJ. The self-medication hypothesis of substance use disorders: a re-consideration and recent applications. *Harv Rev Psychiatry* 1997;4(5):231–44.
- [33] Patton GC, Coffey C, Carlin JB, Degenhardt L, Lynskey M, Hall W. Cannabis use and mental health in young people: cohort study. *BMJ* 2002 Nov 23;325(7374):1195–8.
- [34] Caspi A, Moffitt TE, Cannon M, McClay J, Murray R, Harrington H, et al. Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene X environment interaction. *Biol Psychiatry* 2005;57(10):1117–27.
- [35] Lynskey M, Hall W. The effects of adolescent cannabis use on educational attainment: a review. *Addiction* 2000;95(11):1621–30.
- [36] Degenhardt L, Hall W. Extent of illicit drug use and dependence, and their contribution to the global burden of disease. *Lancet* 2012;379(9810):55–70.